Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2024-01-16

Clinical Trial Update: Study of ARO-ANG3 in Adults With Mixed Dyslipidemia [Phase 2]

View source ↗

Summary

Phase 2 study of ARO-ANG3 in adults with mixed dyslipidemia has completed and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • ARO-ANG3

Snippet

Sponsor: Arrowhead Pharmaceuticals | Conditions: Mixed Dyslipidemia | Phase 2 | Status: COMPLETED | Results posted: 2024-01-16